Immunological and clinicopathological characteristics of C1RL in 2143 glioma patients

doi:10.21203/rs.3.rs-26895/v1

Download PDF

Research article

Immunological and clinicopathological characteristics of C1RL in 2143 glioma patients

https://doi.org/10.21203/rs.3.rs-26895/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 29 Sep, 2020

Read the published version in BMC Cancer →

Version 1

posted

You are reading this older preprint version

Read the latest preprint version →

Glioma is a deadly and immunosuppressive brain tumor. Complement C1r Subcomponent Like (C1RL), as a prognostic biomarker in several kinds of tumors, has attracted increasing attention from oncologists. However, the role of C1RL in glioma remains unclear. Through 2143 glioma patients from 5 public datasets, the relationships between C1RL expression and clinicopathological characteristics were analyzed. Furthermore, the C1RL associated genes were screened and GO analysis was conducted to investigate their biological process enrichment. In addition, tumor purity, leukocytes infiltration and overall survival were calculated based on C1RL expression. We found that C1RL expression was upregulated in glioblastoma (GBM), especially mesenchymal GBM and primary GBM. Increased C1RL accompanied IDH1 wt both in lower grade glioma (LGG) and GBM. C1RL associated genes were mainly enriched in biological processes which are related to immune response. C1RL expression was also correlated with less tumor purity and more M2 macrophage infiltration. Higher C1RL expression predicted unfavorable survival for patients with glioma and therapeutic resistance in GBM. Our results implied that C1RL is involved in immunological activities and is an independent unfavorable prognostic biomarker for patients with glioma. C1RL is a potential immunotherapeutic target for glioma in future clinical practice.

Oncology

Cancer Biology

Glioma

C1RL

immunosuppression

unfavorable survival

therapeutic resistance

Glioblastoma (GBM, WHO grade IV) and lower grade glioma (LGG, WHO grade II and III) are incurable brain tumor. Existing therapeutic strategies only prolong the survival of glioma patients to a limited extent. Patients with glioma eventually die from tumor recurrence, even with aggressive treatment. Novel therapies that have been successful in other tumors, such as PD-1 inhibition^[1] and Bevacizumab^{[2, 3]}, failed to extend the overall survival time of patients with glioma. Tumor treating fields (TTF), a novel therapy which was approved to treat GBM by Food and Drug Administration (FDA) recently, is not widely used in clinical practice because of its high price and difficulty in using^{[4, 5]}. Current poor situation push us to explore the mechanism of glioma development and novel therapy.

Immunosuppressive microenvironment significantly contributes to the progression and therapeutic resistance of glioma. On one hand, glioma cells induce less immune response and more immunosuppression. Compared to other malignancies, glioma accompanies with less mutant burden and then less infiltrating T cells^[6]. GBM cells block T cell activation and proliferation in response to T cell receptor stimulation by generating extracellular vesicles which carrying PD-L1^[7]. Glioma cells promote the expression of PD-L1 on macrophages which are derived from healthy donators^{[8, 9]}. Intratumorally immunosuppressive education from glioma also contributes to the rise of systemic immunosuppressive myeloid-derived suppressor cells (MDSCs)^[10]. On the other hand, brain provides an immunosuppressive bed for glioma. Compared to the melanoma in flank, melanoma in brain accompany with less CD8 T cells^[11]. Moreover, the antigen-specific cytotoxicity is systemically impaired in mice with brain melanoma^[11]. Naïve T cells are sequestered in large numbers in the bone marrow in cancer patients. This phenomenon characterizes a variety of tumors only when tumors are placed into the intracranial compartment^[12].

Complement C1r Subcomponent Like (C1RL) was found as a prognostic marker in hepatocellular carcinoma^[13] and renal cell cancer^[14]. A gene based analysis showed a significant association between non-Hodgkin lymphoma as well as with diffuse large B-cell lymphoma and C1RL gene^[15]. C1RL also mediates the progression of Burkitt's lymphoma^[16]. C1RL is a protein coding gene and associated with Ovary Adenocarcinoma and Leukorrhea. In terms of molecular function, C1RL protein, homologous to C1r, was identified in active form of serine hydrolase^[17]. C1RL protein cleaves prohaptoglobin in the endoplasmic reticulum^[18]. In addition, pro-C1s is also proteolytically cleaved into two fragments of sizes identical with those of the two chains of active C1s by C1RL protein^[19]. However, the immunological and clinicopathological characteristics of C1RL in glioma remain unclear.

In the present study, we employed 2143 glioma specimens from 5 datasets to further explore the clinicopathological and biological characteristics of C1RL in glioma. Clinicopathological features include WHO grades, histology, GBM status, IDH mutation, GBM subtypes, overall survival and therapeutic resistance. Biological process of C1RL associated genes was enriched to explore the biological characteristics of C1RL. Moreover, the relationship between C1RL expression and tumor purity and leukocytes infiltration were analyzed.

Data collection

Five datasets including transcriptome files and the corresponding clinicopathological information for patients who were diagnosed with glioma (WHO II-IV) were downloaded. The microarray dataset of 539 samples (TCGAmic) and the RNA sequencing dataset of 702 samples (TCGAseq) were downloaded from The Cancer Genome Atlas (TCGA, https://xenabrowser.net). The microarray dataset of 301 samples (CGGAmic) and the RNA sequencing dataset of 325 samples (CGGAseq) were downloaded from The Chinese Glioma Genome Atlas (CGGA, http://www.cgga.org.cn/). The microarray dataset of 276 samples (GSE16011mic) was downloaded from Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/).

Statistics of C1RL expressions

Unpaired t test was used in the comparisons of C1RL expressions of two groups. Ordinary one way ANOVA (multiple comparison) was applied to compare C1RL expressions in three or more groups. P<0.05 was considered significant.

C1RL associated genes siftings and GO analyses

Pearson correlation coefficients between C1RL and all other genes were calculated in RStudio 1.1.453 with the algorithm of cor.test. C1RL-associated genes were defined as genes with r value > 0.4 in GBM dataset (TCGAmic) and r > 0.5 in glioma datasets (TCGAseq, CGGAmic, and CGGAseq). All the C1RL associated genes were introduced into DAVID (https://david.ncifcrf.gov/) for further GO analyses. The top 10 terms of biological processes of GO analyses results were listed in Figure 2.

Moreover, the detailed correlation between C1RL and immunosuppressive genes (CD86, LGALS9, and TGFB1) were showed in Figure 3.

Tumor purity and leukocytes infiltration

The ESTIMATE algorithm package was used to analyze the tumor purity. The CIBERSORT tool (https://cibersort.stanford.edu/) was used to evaluate the leukocytes infiltration. The heatmap was produced in MORPHEUS (https://software.broadinstitute.org/morpheus/) online. The color showed the Z score (subtract mean, divide by standard deviation) of all the expression data. The samples were ordered according to the expression of C1RL.

Survival analyses

The log-rank tests and Kaplan Meier survival curves were used to describe the survival differences between two groups. The survival analysis of GSE16011 dataset was conducted in R2 (https://hgserver1.amc.nl/cgi-bin/r2/main.cgi).

C1RL expression was upregulated in GBM, especially mesenchymal GBM, primary GBM and IDH1 wt GBM.

C1RL expression was analyzed according to the WHO classification, GBM subtypes, GBM status and IDH1 mutation status. First of all, the expression of C1RL was always the highest in GBM in 5 datasets according both grading system and histology system (Fig. 1.A-H). But the expression levels of C1RL in GBM samples vary a lot. Furthermore, the C1RL expressions among different subgroups of GBM were analyzed. Among four transcriptomic subgroups of GBM, C1RL expression was always the highest in mesenchymal GBM (Fig. 1.I-L). Secondary GBM was developed from the lower grade glioma and accompanied with lower C1RL than that in primary GBM (Fig. 1.M-N). IDH mutation status is a well-accepted marker for glioma classification. C1RL is higher in IDH1 wt GBM than that in IDH1 mt GBM (Fig. 1.O-Q). In addition, C1RL is higher in IDH1 wt LGG than that in IDH1 mt LGG (Fig. 1.P and Q). These results suggested that higher C1RL expression accompanies higher malignancy in glioma, especially in GBM.

C1RL associated genes enriched in the biological processes of immune response.

The biological function of C1RL, especially in tumor, has not been clarified thoroughly. Therefore, we aimed to speculate the possible biological function of C1RL through the biological function of C1RL associated genes. C1RL associated genes were the genes which have the similar expression trends as C1RL in glioma samples. All the C1RL genes from each dataset were introduced to the GO analysis. The biological processes were listed in reverse order of their p values. The GO analyses showed that C1RL associated genes mainly enriched in the biological processes of immune response, inflammatory response, IFN-γ mediated signaling pathway, and innate immune response (Fig. 2.A-D).

In order to determine whether C1RL plays a positive role in anti-glioma immune response or not, the expression relationship between C1RL and existing biomarkers were analyzed. CD86 protein is the receptor of CTLA4 and mainly expresses on dendritic cells and monocytes. Galectin-9, encoded by LGALS9, was identified as the ligand of Tim-3 and play a key role the apoptosis of T cells. TGFB1 encodes a secreted ligand of the TGF-beta (transforming growth factor-beta) superfamily of proteins. CD86^[20], LGALS9^[21], and TGFB1^[22] play immunosuppressive roles in glioma. Our results showed that C1RL expression exhibited a positive relation to CD86, LGALS9, and TGFB1 (Fig. 3.A-L).

C1RL expression was correlated with less tumor purity and more M2 macrophage infiltration

Immune response is based on the migration of immune cells. Both tumor purity and the infiltration of 22 leukocytes were assessed for each sample from TCGA datasets. The samples were displayed in order of their C1RL expression levels. Both immune score and stromal score exhibited a positive correlation with C1RL expression trends (Fig. 4.A and B, top panels). In addition, the tumor purity showed an inverse correlation with C1RL expression trends (Fig. 4.A and B, middle panels). Moreover, C1RL expression is mostly related to M2 macrophage infiltration among 22 leukocytes (Fig. 4.A and B, bottom panels).

High expression of C1RL predicted unfavorable survival and therapeutic resistance in glioma

The median expression value of C1RL was used to separate samples into two groups. We evaluated the prognostic value of C1RL in four glioma datasets. Patients with glioma containing higher C1RL expression had a significantly shorter survival times than their counterparts in the GSE16011mic, TCGAseq, CGGAmic, and CGGAseq datasets (Fig. 5.A-D). However, histopathology may contribute to these significant differences. Next, we compared the survival times among GBM patients with different C1RL expressions in five datasets. All the survival curves exhibited significant differences (Fig. 5.E-I). Moreover, the effectiveness of well-accepted treatment was evaluated in different C1RL level groups. The primary GBM patients with less C1RL expression showed better response to resection, radio chemotherapy (temozolomide), and standard therapy (Fig. 5.J-L). These results indicate that C1RL may contribute to therapeutic resistance.

C1RL is a negative biomarker for glioma prognosis. C1RL hadn’t been mentioned in cancer until the report of a significant association with non-Hodgkin lymphoma overall as well as with diffuse large B-cell lymphoma for the C1RL gene in 2012^[15]. In recent years, C1RL was reported as a prognostic biomarker in hepatocellular carcinoma^[13] and renal cell cancer^[14]. Our results showed evidences that C1RL highly express on the glioma samples accompanying with bad prognosis. GBM is the WHO grade IV glioma and has the worst prognosis of median overall survival of 14.6 months^[23]. The C1RL expression was always the highest in GBM when it was compared with LGG (Fig. 1.A-H). Unsupervised transcriptome analysis reveals that mesenchymal GBM is related to the worst survival^[24]. The C1RL expression in mesenchymal GBM was higher than that in other GBM subgroups (Fig. 1.I-L). Secondary GBM progresses from LGG within 5–10 years of diagnosis and accompanies with better prognosis than that in primary GBM^[25]. Secondary GBM expressed less C1RL than primary GBM (Fig. 1.M and N). Patients with IDH1 mutant glioma have a better outcome than those with wild-type IDH1 gene^[26]. Less C1RL expressions happened in both IDH1 mutant LGG and IDH1 mutant GBM (Fig. 1.O-Q). C1RL not only predicts higher malignancy but also worse overall survival in glioma. Due to the distinct outcome of the glioma subgroups, the differences of C1RL on different histopathological subgroups (Fig. 1.A-H) may contribute to the differences of survival outcome. We further investigated the survival difference between the high expression group and the low expression group of C1RL in GBM and even primary GBM. The results confirmed that the expression of C1RL was a survival indicator in primary GBM (Fig. 5.F-I). Resection following with chemoradiation was the well accepted strategy for primary GBM patients. Considering the effect from variant therapies, C1RL may play a role in therapeutic resistance (Fig. 5.J-L). Overall, our results indicated that C1RL is a biomarker of poor outcome for glioma patients.

C1RL probably play an important role in glioma immunosuppression. C1RL protein, is confirmed as an active form of serine hydrolase^[17] and cleaves prohaptoglobin and pro-C1s into active forms^[18][19]. On one hand, due to the suppression of lymphocyte function by haptoglobin^[27], C1RL may modulate the immunosuppression of glioma by releasing active haptoglobin. On the other hand, the association of C1s with C1r and C1q, following ligand recognition, triggers the activation of the classical complement pathway^[28]. C1q plays a fundamental role in the pathogenesis of glioma^[29]. Thus, C1RL may trigger the classical complement pathway by activating C1s and then contribute to the pathogenesis of glioma. In addition, accumulated evidences show that C1RL is upregulated in inflammation^[30][31]. GO analyses for C1RL associated genes revealed that they mainly enriched in the biological processes of immune response, inflammatory response, IFN-γ mediated signaling pathway, and innate immune response (Fig. 2.A-D). Furthermore, C1RL has a positive correlation with immunosuppressive markers (Fig. 3.A-L). Less tumor purity and more M2 macrophage predict worse outcome of the patients with glioma^{[32, 33]}. More immune cells, especially M2 macrophages, migrated into glioma which expressing higher C1RL (Fig. 4.A and B). All these results are consisted to the hypothesis that C1RL paly an immunosuppressive role in glioma.

In conclusion, we analyzed the immunological and clinicopathological characteristics of C1RL in 2143 glioma patients from five datasets. The results indicated that C1RL is a negative biomarker for the patients with glioma. Furthermore, C1RL probably play an immunosuppressive role in the pathogenesis of glioma by triggering the activations of haptoglobin and C1s.

Author Contributions Statement

Xuejun Yang and Junyou Wang participated the design of this study. Luqing Tong performed the statistical analysis and drafted the manuscript. Gaojun Lin and Hui Wang carried out data acquisition. All authors have read and approved the final manuscript.

Competing Interests:

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Filley AC, Henriquez M, Dey M. Recurrent glioma clinical trial, CheckMate-143: the game is not over yet. Oncotarget. 2017;8(53):91779–94.
Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, Campone M, Clement PM, Stupp R, Fabbro M, Le RE, Dubois F, Weller M, von DA, Golfinopoulos, Bromberg V, Platten JC, Klein M, van den Bent M. MJ. Lomustine and Bevacizumab in Progressive Glioblastoma. N Engl J Med. 2017;377(20):1954–63.
Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, Aldape KD, Curran WJ, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014;370(8):699–708.
Stupp R, Taillibert S, Kanner A, Read W, Steinberg D, Lhermitte B, Toms S, Idbaih A, Ahluwalia MS, Fink K, Di MF, Lieberman F, Zhu JJ, Stragliotto G, Tran D, Brem S, Hottinger A, Kirson ED, Lavy-Shahaf G, Weinberg U, Kim CY, Paek SH, Nicholas G, Bruna J, Hirte H, Weller M, Palti Y, Hegi ME, Ram Z. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. JAMA. 2017;318(23):2306–16.
Palmer JD, Bhamidipati D, Mehta M, Williams NL, Dicker AP, Werner-Wasik M, Shi W. Treatment recommendations for elderly patients with newly diagnosed glioblastoma lack worldwide consensus. J Neurooncol. 2018;140(2):421–6.
Li B, Severson E, Pignon JC, Zhao H, Li T, Novak J, Jiang P, Shen H, Aster JC, Rodig S, Signoretti S, Liu JS, Liu XS. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174.
Ricklefs FL, Alayo Q, Krenzlin H, Mahmoud AB, Speranza MC, Nakashima H, Hayes JL, Lee K, Balaj L, Passaro C, Rooj AK, Krasemann S, Carter BS, Chen CC, Steed T, Treiber J, Rodig S, Yang K, Nakano I, Lee H, Weissleder R, Breakefield XO, Godlewski J, Westphal M, Lamszus K, Freeman GJ, Bronisz A, Lawler SE, Chiocca EA. Immune evasion mediated by PD-L1 on glioblastoma-derived extracellular vesicles. Sci Adv. 2018;4(3):eaar2766.
Tong L, Li J, Choi J, Pant A, Xia Y, Jackson C, Liu P, Yi L, Boussouf E, Lim M, Yang X. CLEC5A expressed on myeloid cells as a M2 biomarker relates to immunosuppression and decreased survival in patients with glioma. Cancer Gene Ther. 2019.
Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19(12):3165–75.
Chae M, Peterson TE, Balgeman A, Chen S, Zhang L, Renner DN, Johnson AJ, Parney IF. Increasing glioma-associated monocytes leads to increased intratumoral and systemic myeloid-derived suppressor cells in a murine model. Neuro Oncol. 2015;17(7):978–91.
Jackson CM, Kochel CM, Nirschl CJ, Durham NM, Ruzevick J, Alme A, Francica BJ, Elias J, Daniels A, Dubensky TW, Lauer P, Brockstedt DG, Baxi EG, Calabresi PA, Taube JM, Pardo CA, Brem H, Pardoll DM, Lim M, Drake CG. Systemic Tolerance Mediated by Melanoma Brain Tumors Is Reversible by Radiotherapy and Vaccination. Clin Cancer Res. 2016;22(5):1161–72.
Chongsathidkiet P, Jackson C, Koyama S, Loebel F, Cui X, Farber SH, Woroniecka K, Elsamadicy AA, Dechant CA, Kemeny HR, Sanchez-Perez L, Cheema TA, Souders NC, Herndon JE, Coumans JV, Everitt JI, Nahed BV, Sampson JH, Gunn MD, Martuza RL, Dranoff G, Curry WT, Fecci PE. Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors. Nat Med. 2018;24(9):1459–68.
Xu B, Lv W, Li X, Zhang L, Lin J. Prognostic genes of hepatocellular carcinoma based on gene coexpression network analysis. J Cell Biochem. 2019.
Chinello C, Cazzaniga M, De Sio G, Smith AJ, Grasso A, Rocco B, Signorini S, Grasso M, Bosari S, Zoppis I, Mauri G, Magni F. Tumor size, stage and grade alterations of urinary peptidome in RCC. J Transl Med. 2015;13:332.
Bassig BA, Zheng T, Zhang Y, Berndt SI, Holford TR, Hosgood HD, Hu W, Leaderer B, Yeager M, Menashe I, Boyle P, Xu J, Zou K, Zhu Y, Chanock S, Rothman N, Lan Q. Polymorphisms in complement system genes and risk of non-Hodgkin lymphoma. Environ Mol Mutagen. 2012;53(2):145–51.
Han B, Wang S, Zhao H. MicroRNA-21 and microRNA-155 promote the progression of Burkitt's lymphoma by the PI3K/AKT signaling pathway. Int J Clin Exp Pathol. 2020;13(1):89–98.
Navarrete M, Ho J, Krokhin O, Ezzati P, Rigatto C, Reslerova M, Rush DN, Nickerson P, Wilkins JA. Proteomic characterization of serine hydrolase activity and composition in normal urine. Clin Proteomics. 2013;10(1):17.
Wicher KB, Fries E. Prohaptoglobin is proteolytically cleaved in the endoplasmic reticulum by the complement C1r-like protein. Proc Natl Acad Sci U S A. 2004;101(40):14390–5.
Ligoudistianou C, Xu Y, Garnier G, Circolo A, Volanakis JE. A novel human complement-related protein, C1r-like protease (C1r-LP), specifically cleaves pro-C1s. Biochem J. 2005;387(Pt 1):165–73.
Tumangelova-Yuzeir K, Naydenov E, Ivanova-Todorova E, Krasimirova E, Vasilev G, Nachev S, Kyurkchiev D. Mesenchymal Stem Cells Derived and Cultured from Glioblastoma Multiforme Increase Tregs, Downregulate Th17, and Induce the Tolerogenic Phenotype of Monocyte-Derived Cells. Stem Cells Int. 2019. 2019: 6904638.
Yuan F, Ming H, Wang Y, Yang Y, Yi L, Li T, Ma H, Tong L, Zhang L, Liu P, Li J, Lin Y, Yu S, Ren B, Yang X. Molecular and clinical characterization of Galectin-9 in glioma through 1,027 samples. J Cell Physiol. 2020;235(5):4326–34.
Han J, Chen X, Chu J, Xu B, Meisen WH, Chen L, Zhang L, Zhang J, He X, Wang QE, Chiocca EA, Kaur B, Caligiuri MA, Yu J. TGFβ Treatment Enhances Glioblastoma Virotherapy by Inhibiting the Innate Immune Response. Cancer Res. 2015;75(24):5273–82.
Stupp R, Mason WP, van den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Ludwin SK, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005;352(10):987–96.
Wang Q, Hu B, Hu X, Kim H, Squatrito M, Scarpace L, deCarvalho AC, Lyu S, Li P, Li Y, Barthel F, Cho HJ, Lin YH, Satani N, Martinez-Ledesma E, Zheng S, Chang E, Gabriel SCE, Olar A, Lan ZD, Finocchiaro G, Phillips JJ, Berger MS, Gabrusiewicz KR, Wang G, Eskilsson E, Hu J, Mikkelsen T, DePinho RA, Muller F, Heimberger AB, Sulman EP, Nam DH. RGW V. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. Cancer Cell. 2018;33(1):152.
Hu H, Mu Q, Bao Z, Chen Y, Liu Y, Chen J, Wang K, Wang Z, Nam Y, Jiang B, Sa JK, Cho HJ, Her NG, Zhang C, Zhao Z, Zhang Y, Zeng F, Wu F, Kang X, Liu Y, Qian Z, Wang Z, Huang R, Wang Q, Zhang W, Qiu X, Li W, Nam DH, Fan X, Wang J, Jiang T. Mutational Landscape of Secondary Glioblastoma Guides MET-Targeted Trial in Brain Tumor. Cell. 2018;175(6):1665–78.e18.
Yan H, Parsons DW, Jin G, McLendon R, Rasheed BA, Yuan W, Kos I, Batinic-Haberle I, Jones S, Riggins GJ, Friedman H, Friedman A, Reardon D, Herndon J, Kinzler KW, Velculescu VE, Vogelstein B, Bigner DD. IDH1 and IDH2 mutations in gliomas. N Engl J Med. 2009;360(8):765–73.
Sadrzadeh SM, Bozorgmehr J. Haptoglobin phenotypes in health and disorders. Am J Clin Pathol. 2004. 121 Suppl: S97-104.
Lu J, Kishore U. C1 Complex: An Adaptable Proteolytic Module for Complement and Non-Complement Functions. Front Immunol. 2017;8:592.
Mangogna A, Belmonte B, Agostinis C, Zacchi P, Iacopino DG, Martorana A, Rodolico V, Bonazza D, Zanconati F, Kishore U, Bulla R. Prognostic Implications of the Complement Protein C1q in Gliomas. Front Immunol. 2019;10:2366.
Severino P, Ariga SK, Barbeiro HV, de Lima TM, de Paula Silva E, Barbeiro DF, MCC M, Nizet V, Pinheiro dSF. Cathelicidin-deficient mice exhibit increased survival and upregulation of key inflammatory response genes following cecal ligation and puncture. J Mol Med (Berl). 2017;95(9):995–1003.
Shi L, Zhu B, Xu M, Wang X. Selection of AECOPD-specific immunomodulatory biomarkers by integrating genomics and proteomics with clinical informatics. Cell Biol Toxicol. 2018;34(2):109–23.
Zhang C, Cheng W, Ren X, Wang Z, Liu X, Li G, Han S, Jiang T, Wu A. Tumor Purity as an Underlying Key Factor in Glioma. Clin Cancer Res. 2017;23(20):6279–91.
Cai J, Zhang W, Yang P, Wang Y, Li M, Zhang C, Wang Z, Hu H, Liu Y, Li Q, Wen J, Sun B, Wang X, Jiang T, Jiang C. Identification of a 6-cytokine prognostic signature in patients with primary glioblastoma harboring M2 microglia/macrophage phenotype relevance. PLoS One. 2015;10(5):e0126022.

Download PDF

Journal Publication

published 29 Sep, 2020

Read the published version in BMC Cancer →

Version 1

posted

You are reading this older preprint version

Read the latest preprint version →

Immunological and clinicopathological characteristics of C1RL in 2143 glioma patients

Status:

Journal Publication

Version 1

Abstract

Figures

Introduction

Methods And Materials

Results

Discussion

Declarations

References

Status:

Journal Publication

Version 1